SD-101 Dermal Cream (6%)

DRUG4 trials

Sponsors

Scioderm, Inc., Paradigm Therapeutics

Conditions

Epidermolysis BullosaEpidermolysis Bullosa (EB)

Phase 2

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

CompletedNCT02014376

Scioderm, Inc.Epidermolysis Bullosa

Start: 2014-01-06End: 2014-06-24Updated: 2020-01-13

Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

TerminatedNCT02090283

Scioderm, Inc.Epidermolysis Bullosa

Start: 2014-03-26End: 2018-09-14Updated: 2019-11-04

Phase 3

Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

RecruitingNCT07482787

Paradigm TherapeuticsEpidermolysis Bullosa (EB)

Start: 2026-07-21End: 2027-06-17Target: 80Updated: 2026-09-04

An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

Not yet recruitingNCT07482813

Paradigm TherapeuticsEpidermolysis Bullosa (EB)

Start: 2026-11-15End: 2027-10-19Target: 80Updated: 2026-09-09

Related Papers

Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study).

2020-06-2313 citations